BERKELEY HEIGHTS, N.J., Nov. 14, 2011 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), announced today its financial results and business highlights for the third quarter of 2011. The Company’s net loss applicable to common shareholders for the third quarter of 2011 was $3.6 million, or $0.07 per basic and diluted share, compared to a net loss applicable to common shareholders of $4.0 million or $0.11 per basic and diluted share, for the third quarter of 2010. For the nine months ended September 30, 2011, the Company reported a net loss applicable to common shareholders of $12.1 million, or $0.25 per basic and diluted share, compared to a net loss of $16.3 million, or $0.47 per basic and diluted share, for the nine months ended September 30, 2010.
